We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Psychedelics – News and Features

Why Does Ketamine Fight Depression? Finding Answers at BNA 2019 content piece image
Article

Why Does Ketamine Fight Depression? Finding Answers at BNA 2019

A significant minority of major depressive disorder patients don’t respond to currently available antidepressant medication. A newly approved treatment, based on the "club drug" ketamine, could change that. In a session at the British Neuroscience Association’s Festival of Neuroscience 2019, the potential mechanisms of ketamine’s antidepressant action were put under examination.
News

Ketamine Reverses Neural Changes Underlying Depression-related Behaviors in Mice

Researchers have identified ketamine-induced brain-related changes that are responsible for maintaining the remission of behaviors related to depression in mice – findings that may help researchers develop interventions that promote lasting remission of depression in humans.
News

Psychedelic Drug MDMA May Reawaken ‘Critical Period’ in Brain to Help Treat PTSD

Johns Hopkins scientists have used MDMA to reopen a “critical period,” when the brain is sensitive to learning the reward value of social behaviors.
News

Fast-acting Psychedelic Eases Depression and Anxiety

Researchers have discovered that use of the synthetic psychedelic, 5-methocy-N,-N-dimethyltryptamine, appears to be associated with unintended improvements in self-reported depression and anxiety when given in a ceremonial group setting.
News

Residue in Your Fingerprints Could Reveal Drug Use

Drug abuse has become an increasingly serious problem all over the world. Could fingerprinting be an appropriate method for determining whether a person has taken drugs?
News

FDA Approves Ketamine-derived Nasal Spray for Depression

The U.S. Food and Drug Administration has approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them.
News

Psychedelic Microdosing in Rats Shows Beneficial Effects

The growing popularity of microdosing – taking tiny amounts of psychedelic drugs to boost mood and mental acuity – is based on anecdotal reports of its benefits. Now, a study in rats by researchers at the University of California, Davis suggests microdosing can provide relief for symptoms of depression and anxiety, but also found potential negative effects.
News

Not All Sleep is Equal When It Comes to Cleaning the Brain

New research shows how the depth of sleep can impact our brain’s ability to efficiently wash away waste and toxic proteins. Because sleep often becomes increasingly lighter and more disrupted as we become older, the study reinforces and potentially explains the links between aging, sleep deprivation, and heightened risk for Alzheimer’s disease.

News

Antidepressant Based on Ketamine Gets Backing From FDA Advisory Group

A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.
News

Mega Docking Library Set to Speed Drug Discovery

Researchers have launched an ultra-large virtual docking library expected to grow to more than 1 billion molecules by next year. It will expand by 1000-fold the number of such “make-on-demand” compounds readily available to scientists for chemical biology and drug discovery.
Advertisement